Wicki Andreas's Form 4 filing
Harmony Biosciences Holdings, Inc. (HRMY) · filed Nov 17, 2021
- Accession no.
- 0001104659-21-140749
- Filed
- Nov 17, 2021
- Trade date
- Nov 15-17, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $2.88M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wicki AndreasCIK 0001511472 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2021 | Common Stock | SSaleDisposed | −35,600 | $42.08F1 | −$1,498,048 | 4,609,179 | Indirect | |
| Nov 16, 2021 | Common Stock | SSaleDisposed | −32,251 | $41.09F3 | −$1,325,193.59 | 4,573,928 | Indirect | |
| Nov 17, 2021 | Common Stock | SSaleDisposed | −1,417 | $41.25 | −$58,451.25 | 4,572,511 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.80 to $42.91, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to 41.09, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (3) of this Form 4.
Referenced by the price of 1 transaction in Table I.